# To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

> **NCT02807051** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 20 (actual)

## Conditions studied

- Drug Interaction Study

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Clarithromycin
- **DRUG:** Pacritinib and Clarithromycin

## Key facts

- **NCT ID:** NCT02807051
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02807051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02807051, "To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02807051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*